Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Cancers
|
November 13, 2025
Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years
María Victoria Mateos, Evangelos Terpos, Sara Martínez, et al.
Marine Drugs
|
October 21, 2009
Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium
Herlinde Dumez, Enrique Gallardo, Stephane Culine, et al.
Marine Drugs
|
July 13, 2011
Plitidepsin has a safe cardiac profile: a comprehensive analysis
Arturo Soto-Matos, Sergio Szyldergemajn, Sonia Extremera, et al.
Anti-Cancer Drugs
|
December 16, 2016
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas
Sandrine Aspeslagh, Mark Stein, Rastilav Bahleda, et al.
Clinical Breast Cancer
|
June 9, 2016
Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene
Ahmad Awada, Javier Cortés, Miguel Martín, et al.
Investigational New Drugs
|
August 3, 2024
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
Mohammad H Ghalib, Mariano Provencio Pulla, Maria J De Miguel Luken, et al.
Haematologica
|
October 16, 2012
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
Vincent Ribrag, Dolores Caballero, Christophe Fermé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
María Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
Annals of Hematology
|
June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Ivan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Cancers
|
November 13, 2025
Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years
María Victoria Mateos, Evangelos Terpos, Sara Martínez, et al.
Marine Drugs
|
October 21, 2009
Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium
Herlinde Dumez, Enrique Gallardo, Stephane Culine, et al.
Marine Drugs
|
July 13, 2011
Plitidepsin has a safe cardiac profile: a comprehensive analysis
Arturo Soto-Matos, Sergio Szyldergemajn, Sonia Extremera, et al.
Anti-Cancer Drugs
|
December 16, 2016
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas
Sandrine Aspeslagh, Mark Stein, Rastilav Bahleda, et al.
Clinical Breast Cancer
|
June 9, 2016
Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene
Ahmad Awada, Javier Cortés, Miguel Martín, et al.
Investigational New Drugs
|
August 3, 2024
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
Mohammad H Ghalib, Mariano Provencio Pulla, Maria J De Miguel Luken, et al.
Haematologica
|
October 16, 2012
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
Vincent Ribrag, Dolores Caballero, Christophe Fermé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
María Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
Annals of Hematology
|
June 27, 2019
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Ivan Spicka, Enrique M Ocio, Heather E Oakervee, et al.
Page
of 1